Distinct and Overlapping Effector Functions of Expanded Human CD4+, CD8α+ and CD4-CD8α- Invariant Natural Killer T Cells

CD1d-restricted invariant natural killer T (iNKT) cells have diverse immune stimulatory/regulatory activities through their ability to release cytokines and to kill or transactivate other cells. Activation of iNKT cells can protect against multiple diseases in mice but clinical trials in humans have had limited impact. Clinical studies to date have targeted polyclonal mixtures of iNKT cells and we proposed that their subset compositions will influence therapeutic outcomes. We sorted and expanded iNKT cells from healthy donors and compared the phenotypes, cytotoxic activities and cytokine profiles of the CD4+, CD8α+ and CD4−CD8α− double-negative (DN) subsets. CD4+ iNKT cells expanded more readily than CD8α+ and DN iNKT cells upon mitogen stimulation. CD8α+ and DN iNKT cells most frequently expressed CD56, CD161 and NKG2D and most potently killed CD1d+ cell lines and primary leukemia cells. All iNKT subsets released Th1 (IFN-γ and TNF-α) and Th2 (IL-4, IL-5 and IL-13) cytokines. Relative amounts followed a CD8α>DN>CD4 pattern for Th1 and CD4>DN>CD8α for Th2. All iNKT subsets could simultaneously produce IFN-γ and IL-4, but single-positivity for IFN-γ or IL-4 was strikingly rare in CD4+ and CD8α+ fractions, respectively. Only CD4+ iNKT cells produced IL-9 and IL-10; DN cells released IL-17; and none produced IL-22. All iNKT subsets upregulated CD40L upon glycolipid stimulation and induced IL-10 and IL-12 secretion by dendritic cells. Thus, subset composition of iNKT cells is a major determinant of function. Use of enriched CD8α+, DN or CD4+ iNKT cells may optimally harness the immunoregulatory properties of iNKT cells for treatment of disease.

[1]  D. Pellicci,et al.  Differential antitumor immunity mediated by NKT cell subsets in vivo , 2005, The Journal of experimental medicine.

[2]  G. Besra,et al.  Alteration of the relative levels of iNKT cell subsets is associated with chronic mycobacterial infections. , 2008, Clinical immunology.

[3]  T. Yamamura,et al.  The clinical implication and molecular mechanism of preferential IL-4 production by modified glycolipid-stimulated NKT cells. , 2004, The Journal of clinical investigation.

[4]  Chi‐Huey Wong,et al.  Potent immune-modulating and anticancer effects of NKT cell stimulatory glycolipids , 2007, Proceedings of the National Academy of Sciences.

[5]  T. Yamamura,et al.  A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells , 2001, Nature.

[6]  A. Rachitskaya,et al.  Cutting Edge: NKT Cells Constitutively Express IL-23 Receptor and RORγt and Rapidly Produce IL-17 upon Receptor Ligation in an IL-6-Independent Fashion1 , 2008, The Journal of Immunology.

[7]  Jay A. Berzofsky,et al.  NKT cell–mediated repression of tumor immunosurveillance by IL-13 and the IL-4R–STAT6 pathway , 2000, Nature Immunology.

[8]  Michael B Brenner,et al.  CD1: antigen presentation and T cell function. , 2004, Annual review of immunology.

[9]  H. Hirai,et al.  Cutting Edge: Analysis of Human Vα24+CD8+ NK T Cells Activated by α-Galactosylceramide-Pulsed Monocyte-Derived Dendritic Cells , 2002, The Journal of Immunology.

[10]  R. Seeger,et al.  Human NKT Cells Mediate Antitumor Cytotoxicity Directly by Recognizing Target Cell CD1d with Bound Ligand or Indirectly by Producing IL-2 to Activate NK Cells1 , 2001, The Journal of Immunology.

[11]  G. Besra,et al.  α-Galactosylceramide Analogs with Weak Agonist Activity for Human iNKT Cells Define New Candidate Anti-Inflammatory Agents , 2010, PloS one.

[12]  R. Steinman,et al.  Innate Vα14+ natural killer T cells mature dendritic cells, leading to strong adaptive immunity , 2007, Immunological reviews.

[13]  G. Bubley,et al.  Loss of IFN-γ Production by Invariant NK T Cells in Advanced Cancer1 , 2001, The Journal of Immunology.

[14]  S. Nuti,et al.  CD1d-restricted Help To B Cells By Human Invariant Natural Killer T Lymphocytes , 2003, The Journal of experimental medicine.

[15]  L. Teyton,et al.  Testing the NKT cell hypothesis of human IDDM pathogenesis. , 2002, The Journal of clinical investigation.

[16]  Y. Okamoto,et al.  A Phase I Study of In vitro Expanded Natural Killer T Cells in Patients with Advanced and Recurrent Non–Small Cell Lung Cancer , 2006, Clinical Cancer Research.

[17]  L. Jones,et al.  CD4−CD8αα Subset of CD1d-Restricted NKT Cells Controls T Cell Expansion1 , 2004, The Journal of Immunology.

[18]  M. Nieda,et al.  Differential proliferative response of NKT cell subpopulations to in vitro stimulation in presence of different cytokines , 2004, European journal of immunology.

[19]  G. Berry,et al.  CD4+ invariant T-cell-receptor+ natural killer T cells in bronchial asthma. , 2006, The New England journal of medicine.

[20]  A. Ohta,et al.  The Natural Killer T (NKT) Cell Ligand α-Galactosylceramide Demonstrates Its Immunopotentiating Effect by Inducing Interleukin (IL)-12 Production by Dendritic Cells and IL-12 Receptor Expression on NKT Cells , 1999, The Journal of experimental medicine.

[21]  M. Taniguchi,et al.  Functionally distinct NKT cell subsets and subtypes , 2005, The Journal of experimental medicine.

[22]  L. Kaer,et al.  The natural killer T-cell ligand α-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice , 2001, Nature Medicine.

[23]  Kumud Kumari,et al.  Characterization of human invariant natural killer T subsets in health and disease using a novel invariant natural killer T cell‐clonotypic monoclonal antibody, 6B11 , 2007, Immunology.

[24]  R. Noelle,et al.  Cellular sources and immune functions of interleukin-9 , 2010, Nature Reviews Immunology.

[25]  S. Balk,et al.  Requirements for CD1d Recognition by Human Invariant Vα24+ CD4−CD8− T Cells , 1997, The Journal of experimental medicine.

[26]  M. Smyth,et al.  Presumed guilty: natural killer T cell defects and human disease , 2011, Nature Reviews Immunology.

[27]  C. Leemans,et al.  Peripheral blood IFN‐γ‐secreting Vα24+Vβ11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load , 2005 .

[28]  H. Lyerly,et al.  Ex vivo expanded human CD4+ regulatory NKT cells suppress expansion of tumor antigen-specific CTLs. , 2005, International immunology.

[29]  D. Doherty,et al.  NKT Cells from Normal and Tumor-Bearing Human Livers Are Phenotypically and Functionally Distinct from Murine NKT Cells 1 , 2003, The Journal of Immunology.

[30]  Takashi Yamamura,et al.  Functionally Distinct Subsets of CD1d-restricted Natural Killer T Cells Revealed by CD1d Tetramer Staining , 2002, The Journal of experimental medicine.

[31]  Hiroshi Sato,et al.  Requirement for Vα14 NKT Cells in IL-12-Mediated Rejection of Tumors , 1997 .

[32]  L. Rogge,et al.  Proinflammatory Environment Dictates the IL-17–Producing Capacity of Human Invariant NKT Cells , 2011, The Journal of Immunology.

[33]  N. Ohkohchi,et al.  Mechanism of NKT Cell‐Mediated Transplant Tolerance , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[34]  Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients , 2005, The Journal of experimental medicine.

[35]  M. Nieda,et al.  Comparative gene expression analysis of NKT cell subpopulations , 2006, Journal of leukocyte biology.

[36]  R. Proia,et al.  Lysosomal Glycosphingolipid Recognition by NKT Cells , 2004, Science.

[37]  M. Tsuji,et al.  Superior Protection against Malaria and Melanoma Metastases by a C-glycoside Analogue of the Natural Killer T Cell Ligand α-Galactosylceramide , 2003, The Journal of experimental medicine.

[38]  Albert Bendelac,et al.  The biology of NKT cells. , 2007, Annual review of immunology.

[39]  G. Mayrhofer,et al.  Impaired Clearance of Herpes Simplex Virus Type 1 From Mice Lacking CD1d or NKT Cells Expressing the Semivariant Vα14-Jα281 TCR1 , 2003, The Journal of Immunology.

[40]  T. Yamamura,et al.  Invariant NKT Cells Biased for IL-5 Production Act as Crucial Regulators of Inflammation1 , 2007, The Journal of Immunology.

[41]  E. Butcher,et al.  Distinct subsets of human Valpha24-invariant NKT cells: cytokine responses and chemokine receptor expression. , 2002, Trends in immunology.

[42]  河野 鉄.  CD1d-restricted and TCR-mediated activation of V α14 NKT cells by glycosylceramides , 2000 .

[43]  S. Porcelli,et al.  CD1-restricted T cells in host defense to infectious diseases. , 2007, Current topics in microbiology and immunology.

[44]  國井 直樹.  Combination therapy of in vitro expanded natural killer T cells and α-galactosylceramide-pulsed antigen presenting cells in patients with recurrent head and neck carcinoma , 2008 .

[45]  F. Finkelman,et al.  Antigen-Induced Increases in Pulmonary Mast Cell Progenitor Numbers Depend on IL-9 and CD1d-Restricted NKT Cells1 , 2009, The Journal of Immunology.

[46]  M. Nieda,et al.  Analysis of the effect of different NKT cell subpopulations on the activation of CD4 and CD8 T cells, NK cells, and B cells. , 2006, Experimental hematology.

[47]  D. Ho,et al.  Recognition of bacterial glycosphingolipids by natural killer T cells , 2005, Nature.

[48]  K. Nagahira,et al.  Murine NKT cells produce Th17 cytokine interleukin-22. , 2009, Cellular immunology.

[49]  D. Speiser,et al.  Enrichment of Human CD4+ Vα24/Vβ11 Invariant NKT Cells in Intrahepatic Malignant Tumors 1 , 2009, The Journal of Immunology.

[50]  Mario Roederer,et al.  A live-cell assay to detect antigen-specific CD4+ T cells with diverse cytokine profiles , 2005, Nature Medicine.

[51]  S. Matsushita,et al.  Distinct subsets of human invariant NKT cells differentially regulate T helper responses via dendritic cells , 2008, European journal of immunology.

[52]  G. Besra,et al.  NK T cells provide lipid antigen-specific cognate help for B cells , 2008, Proceedings of the National Academy of Sciences.

[53]  L. Graça,et al.  Identification of Regulatory Foxp3+ Invariant NKT Cells Induced by TGF-β , 2010, The Journal of Immunology.

[54]  L. Teyton,et al.  Distinct Functional Lineages of Human Vα24 Natural Killer T Cells , 2002, The Journal of experimental medicine.

[55]  W. Paul,et al.  Nonredundant Roles for CD1d-restricted Natural Killer T Cells and Conventional CD4+ T Cells in the Induction of Immunoglobulin E Antibodies in Response to Interleukin 18 Treatment of Mice , 2003, The Journal of experimental medicine.

[56]  D. Godfrey,et al.  α/β–T Cell Receptor (TCR)+CD4−CD8− (NKT) Thymocytes Prevent Insulin-dependent Diabetes Mellitus in Nonobese Diabetic (NOD)/Lt Mice by the Influence of Interleukin (IL)-4 and/or IL-10 , 1998, The Journal of experimental medicine.

[57]  T. Iizasa,et al.  A Phase I Study of α-Galactosylceramide (KRN7000)–Pulsed Dendritic Cells in Patients with Advanced and Recurrent Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[58]  S. Ullrich,et al.  Immune suppression and skin cancer development: regulation by NKT cells , 2000, Nature Immunology.

[59]  Hiroshi Sato,et al.  CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. , 1997, Science.

[60]  G. Giaccone,et al.  A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[61]  D. Doherty,et al.  Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide. , 2011, Clinical immunology.

[62]  T. Yamamura,et al.  Th2 bias of CD4+ NKT cells derived from multiple sclerosis in remission. , 2003, International immunology.